12-Jun-2026 19:06:10

💊 AUROBINDO PHARMA: US FDA CLASSIFIES EUGIA UNIT-III INSPECTION AS OAI ⚠️

• 🇺🇸 US FDA has classified inspection of Eugia Unit-III (formulation facility) as Official Action Indicated (OAI) • 🏭 Facility is located at Pashamylaram, Telangana and is a wholly owned subsidiary of Aurobindo Pharma • 📅 US FDA inspection was conducted from Jan 27 to Feb 6, 2026 • 📝 Inspection had concluded with 11 observations • 📩 Company received the OAI classification communication on June 12, 2026 • 📊 Aurobindo stated there is no impact on financials or operations due to this action 🔴 Impact: Negative (OAI classification is a stricter US FDA regulatory status and may increase compliance scrutiny on the facility)

AUROBINDO PHARMA LTD

← Back to feed